Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Cardiovascular Outcomes with Once-Weekly GLP-1 RAs: Clinical and Economic Implications
Michael Heile, Kathleen Wyne, Liana K. Billings, et al.
Journal of Managed Care & Specialty Pharmacy (2018) Vol. 24, Iss. 9-a Suppl, pp. S42-S52
Open Access | Times Cited: 10

Showing 10 citing articles:

Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes: Their Use and Differential Features
Katherine A. Lyseng‐Williamson
Clinical Drug Investigation (2019) Vol. 39, Iss. 8, pp. 805-819
Open Access | Times Cited: 64
Switching Between Glucagon-Like Peptide-1 Receptor Agonists: Rationale and Practical Guidance
Jaime P. Almandoz, Ildiko Lingvay, Javier Morales, et al.
Clinical Diabetes (2020) Vol. 38, Iss. 4, pp. 390-402
Open Access | Times Cited: 56
Dulaglutide inhibits high glucose- induced endothelial dysfunction and NLRP3 inflammasome activation
Xiaojia Luo, Yongmei Hu, Sen He, et al.
Archives of Biochemistry and Biophysics (2019) Vol. 671, pp. 203-209
Closed Access | Times Cited: 54
GLP-1 medications versus surgery and balloon: evaluating cost-benefit in weight loss
Carlos Salazar, Secundino López, Camilo Rı́os, et al.
International Surgery Journal (2025) Vol. 12, Iss. 5, pp. 884-891
Open Access
Does Incretin Agonism Have Sustainable Efficacy?
Sok‐Ja Janket, Miyo K. Chatanaka, Dorsa Sohaei, et al.
Cells (2024) Vol. 13, Iss. 22, pp. 1842-1842
Open Access | Times Cited: 1
Obesity Medications and Their Impact on Cardiovascular Health: A Narrative Review
Kazi N. Islam, Rahib K Islam, Victoria T Tong, et al.
Cureus (2024)
Open Access | Times Cited: 1
Glucagon-Like Peptide-1 Receptor Agonists in Patients with Type 2 Diabetes: Prescription According to Reimbursement Constraints and Guideline Recommendations in Catalonia
Josep Franch‐Nadal, Manel Mata‐Cases, Emilio Ortega, et al.
Journal of Clinical Medicine (2019) Vol. 8, Iss. 9, pp. 1389-1389
Open Access | Times Cited: 8
Impact of polyethylene glycol loxenatide on cardiovascular outcomes in patients with type 2 diabetes: study protocol for a multicentre, randomised, double-blind, placebo-controlled trial (BALANCE-3)
Yun Xie, Jian Kuang, Quanmin Li, et al.
BMJ Open (2023) Vol. 13, Iss. 5, pp. e069080-e069080
Open Access | Times Cited: 2
Diabetes tipo 2: contexto fisiopatológico e atualização terapêutica com o uso da semaglutida
Welton Gomes de Paula, Rodrigo Braga Pacheco, Clara Oliveira Noronha Neves, et al.
Revista Eletrônica Acervo Médico (2024) Vol. 24, pp. e16285-e16285
Open Access
Application prospects of glucagon-like peptide-1 receptor agonists in treatment of metabolic diseases
Qiang Zhang, Xiufang Zhang, Chun-Yan Niu
Shijie huaren xiaohua zazhi (2020) Vol. 28, Iss. 11, pp. 393-400
Open Access
Page 1

Scroll to top